Double TKI Therapy Improves Responses in MET Amplification-Driven EGFR-Mutant Non-Small Cell Lung Cancer

Oncology Times - OncTimes Talk

Among patients with non-small cell lung cancers driven by mutations in the epidermal growth factor receptor (EGFR), those with MET-amplification can now be selected for therapy with two tyrosine kinase inhibitor drugs, not just standard osimertinib. That’s according to conclusions from the INSIGHT 2 study reported at the AACR-NCI-EORTC international conference on Molecular Targets and Cancer Therapeutics.

Presenting author Xiuning Le, MD, PhD, from the MD Anderson Cancer Center in Houston, Texas, has been talking with OncTimes Talk’s Peter Goodwin about her group’s study in which osimertinib was combined with the MET-tyrosine kinase inhibitor tepotinib in patients who tested positive for MET-amplification.